TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER Drug Patent Profile

When do Tobramycin Sulfate In Sodium Chloride 0.9% In Plastic Container patents expire, and what generic alternatives are available?

Tobramycin Sulfate In Sodium Chloride 0.9% In Plastic Container is a drug marketed by Hospira and is included in one NDA.

The generic ingredient in TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is tobramycin sulfate. There are eighteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tobramycin sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tobramycin Sulfate In Sodium Chloride 0.9% In Plastic Container

A generic version of TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER was approved as tobramycin sulfate by HIKMA on April 26^th, 1991.

Summary for TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	5
DailyMed Link:	TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Madonna Magdy Fahmy	Early Phase 1
Osteal Therapeutics, Inc.	Phase 2
Joint Purification Systems	Phase 2

See all TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER clinical trials

US Patents and Regulatory Information for TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	tobramycin sulfate	INJECTABLE;INJECTION	063081-003	Jul 31, 1990		DISCN	No	No
Hospira	TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	tobramycin sulfate	INJECTABLE;INJECTION	063081-006	Jun 2, 1993		DISCN	No	No
Hospira	TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	tobramycin sulfate	INJECTABLE;INJECTION	063081-001	Jul 31, 1990		DISCN	No	No

Tobramycin Sulfate in Sodium Chloride 0.9% Injection Market Analysis

Last updated: February 19, 2026

Market Summary

Tobramycin sulfate in sodium chloride 0.9% injection, a critical antibiotic therapy, faces a stable but competitive market landscape. The drug primarily serves the treatment of serious bacterial infections, particularly in hospital and critical care settings. Patent expirations have led to a robust generic market, driving price competition and emphasizing market share acquisition through cost-effectiveness and supply chain reliability. Future growth is anticipated to be moderate, influenced by antibiotic resistance trends, hospital formularies, and the emergence of novel therapeutic alternatives.

Market Dynamics

What are the primary indications and patient populations for tobramycin sulfate in sodium chloride 0.9% injection?

Tobramycin sulfate in sodium chloride 0.9% injection is indicated for the treatment of serious infections caused by susceptible strains of microorganisms, including Pseudomonas aeruginosa, species of Staphylococcus, Streptococcus, Enterobacter, Escherichia coli, Klebsiella, Proteus, Serratia, and Bacteroides. These infections commonly include:

• Lower respiratory tract infections: Pneumonia and bronchopneumonia.
• Urinary tract infections: Complicated and uncomplicated.
• Central nervous system infections: Meningitis, particularly when other agents are contraindicated.
• Bacteremia and septicemia: Systemic infections.
• Intra-abdominal infections: Peritonitis and abscesses.
• Skin and soft tissue infections: Complicated cellulitis and dermal infections.
• Bone and joint infections: Osteomyelitis and septic arthritis.
• Gastrointestinal infections: Certain cases of severe diarrhea.

The primary patient populations receiving this therapy are hospitalized individuals with moderate to severe infections, particularly those admitted to intensive care units (ICUs). It is also utilized in patients with compromised immune systems, cystic fibrosis patients with pulmonary exacerbations, and individuals with specific genitourinary or respiratory conditions that predispose them to bacterial infections. The formulation in 0.9% sodium chloride is standard for intravenous administration, ensuring compatibility and physiological balance.

What is the current patent landscape and generic market penetration?

The original patents protecting tobramycin sulfate have long expired. This has resulted in a mature generic market with widespread availability from multiple manufacturers. The absence of market exclusivity for branded tobramycin sulfate has shifted the competitive focus to manufacturing efficiency, cost of goods, and market access through hospital procurement contracts and group purchasing organizations (GPOs).

Key aspects of the patent and generic landscape include:

• Original Patents: Expired in the late 20th century.
• Generic Competition: High. Numerous pharmaceutical companies manufacture and market generic tobramycin sulfate in 0.9% sodium chloride injection.
• Market Exclusivity: None. No significant patent-protected formulations or delivery systems currently dominate the market.
• Regulatory Approvals: Generic versions are approved by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) based on bioequivalence studies.
• Pricing: Competitive pricing is a defining characteristic of the generic market. Manufacturers compete on price to secure contracts and market share.

What are the key drivers and restraints impacting market growth?

Market Drivers:

• Prevalence of Bacterial Infections: Continued incidence of serious bacterial infections, especially in hospital settings and among immunocompromised populations, sustains demand.
• Antibiotic Resistance Trends: While a broader trend, the emergence of multi-drug resistant organisms (MDROs) can, in some specific cases, lead to the continued or renewed use of older, broader-spectrum antibiotics like tobramycin, particularly when susceptibility testing confirms efficacy.
• Hospital Formularies: Inclusion on hospital formularies and inclusion in GPO contracts are critical for market access and consistent sales volume.
• Cost-Effectiveness: As a generic drug, tobramycin sulfate offers a cost-effective treatment option compared to newer, proprietary antibiotics, making it a preferred choice in resource-constrained environments or for routine treatment protocols.
• Availability of Established Infrastructure: Healthcare systems have well-established protocols and supply chains for administering intravenous antibiotics, supporting continued use.

Market Restraints:

• Antibiotic Stewardship Programs: Widespread implementation of antibiotic stewardship programs aims to optimize antibiotic use, often favoring narrower-spectrum agents or newer antibiotics with improved safety profiles when appropriate, potentially limiting tobramycin use in certain scenarios.
• Emergence of Novel Antibiotics: Development and adoption of new antibiotic classes or agents with broader coverage, improved efficacy against resistant strains, or better safety profiles can displace older agents.
• Adverse Event Profile: Tobramycin has a known profile of nephrotoxicity and ototoxicity, necessitating careful monitoring and dose adjustment, which can sometimes favor alternative treatments with lower toxicity.
• Competition from Other Aminoglycosides: Other aminoglycosides like gentamicin and amikacin compete within the same therapeutic class, with specific indications and resistance patterns influencing choice.
• IV Administration Requirement: The need for intravenous administration limits its use to inpatient or closely monitored outpatient settings, unlike oral antibiotics.

Financial Trajectory

What are the estimated market sizes and revenue projections?

The global market for tobramycin sulfate in sodium chloride 0.9% injection is characterized by high volume and low unit price due to its generic status. Precise aggregate market size figures are often proprietary and vary based on the scope of analysis (e.g., by region, by dosage form). However, industry reports generally place the injectable antibiotic market, which includes tobramycin, in the tens of billions of U.S. dollars globally.

For tobramycin sulfate in 0.9% sodium chloride injection specifically:

• Estimated Market Size (Global): Difficult to isolate precisely, but likely in the range of USD 200 million to USD 500 million annually, considering its broad use in hospital settings for various infections. This figure is based on typical market penetration for established generic injectables with broad indications.
• Revenue Projections: The market is expected to exhibit low single-digit compound annual growth rate (CAGR), projected between 1% and 3% over the next five years (2024-2029). This moderate growth is driven by consistent demand for established antibiotics in treating common bacterial infections, offset by the pressures of antibiotic stewardship and competition.

These projections are sensitive to fluctuations in hospital purchasing power, the introduction of new treatment guidelines, and the overall economic health of healthcare systems worldwide.

Who are the key manufacturers and suppliers in this market?

The market for tobramycin sulfate in sodium chloride 0.9% injection is fragmented, with a substantial number of generic manufacturers. The key players are typically those with robust sterile injectable manufacturing capabilities and established distribution networks. While specific market share data is fluid, leading generic manufacturers include:

• Fresenius Kabi: A major player in generic injectable pharmaceuticals, including antibiotics.
• Hikma Pharmaceuticals: Known for its broad portfolio of injectable generics.
• Baxter International: A significant supplier of intravenous solutions and generic drug products.
• Sandoz (a Novartis company): A leading global generic pharmaceuticals company.
• Teva Pharmaceutical Industries: One of the world's largest generic drug manufacturers.
• Mylan (now Viatris): Another significant provider of generic injectable medicines.
• Various regional manufacturers: Numerous smaller and regional players also contribute to supply, particularly in specific geographic markets.

These companies often compete on price, contract terms, and supply chain reliability.

What pricing trends and reimbursement policies are relevant?

Pricing Trends:

• Generic Pricing: Prices are highly competitive and largely dictated by supply and demand dynamics, contract negotiations with hospitals and GPOs, and manufacturing costs. Unit prices are generally low.
• Contractual Agreements: The majority of sales occur through negotiated contracts, often involving tiered pricing based on volume.
• Wholesale Acquisition Cost (WAC): While WAC exists, actual transacted prices are significantly lower due to discounts and rebates negotiated by purchasers.
• International Variations: Pricing can vary substantially between countries due to differences in healthcare systems, regulatory environments, and local competition.

Reimbursement Policies:

• Hospital Inpatient Care: In the United States, tobramycin sulfate for inpatient hospital use is typically reimbursed as part of the hospital's overall operating costs under Medicare and commercial insurance plans. It falls under the Prospective Payment System (PPS) for inpatient services, where drugs are not typically billed separately unless they are considered exceptionally high-cost or have specific pass-through status, which is unlikely for generic tobramycin.
• Outpatient Care: For outpatient settings, reimbursement depends on the specific payer and facility. Administration fees for IV infusions are usually covered, along with the drug cost if it is on the payer's formulary or through a prior authorization process.
• Formulary Status: Hospital and payer formularies play a crucial role. Inclusion on a formulary generally ensures coverage and preferred use.
• Global Reimbursement: In other countries, reimbursement mechanisms vary, often involving national health services, social insurance schemes, or private insurance, with drug pricing and reimbursement determined by national bodies and pricing committees.

Competitive Landscape

How do different manufacturers differentiate their tobramycin sulfate products?

In the generic tobramycin sulfate market, differentiation is subtle and primarily centers on factors other than the active pharmaceutical ingredient itself, as the drug is bioequivalent across manufacturers. Differentiation strategies include:

• Supply Chain Reliability and Security: Ensuring consistent availability and a robust supply chain is paramount. Manufacturers with strong track records in avoiding stock-outs gain a competitive advantage.
• Packaging and Presentation: While the drug is standardized, variations in vial sizes, container types (e.g., pre-filled bags, standard vials), and labeling can influence hospital preference and ease of use in clinical settings.
• Customer Service and Support: Responsiveness to order inquiries, logistical support, and strong relationships with procurement departments are key differentiators.
• Pricing and Contract Terms: The ability to offer competitive pricing and flexible contract terms (e.g., volume discounts, extended payment terms) is a primary competitive lever.
• Manufacturing Excellence and Quality Control: Adherence to stringent Good Manufacturing Practices (GMP) and a reputation for high-quality products build trust and preference.

What are the emerging threats and opportunities in the market?

Emerging Threats:

• Increased Antibiotic Stewardship Stringency: More aggressive implementation of antibiotic stewardship could lead to greater scrutiny and potential restriction of tobramycin use, favoring narrower-spectrum or newer agents, even if tobramycin remains effective.
• Development of Novel Aminoglycoside Resistance: While resistance to tobramycin is a known issue, the emergence of new resistance mechanisms within the aminoglycoside class could further limit its utility.
• Consolidation of GPOs and Hospital Systems: Larger purchasing entities can exert greater price pressure, potentially squeezing manufacturer margins.
• Supply Chain Vulnerabilities: Geopolitical instability, raw material shortages, or manufacturing disruptions could impact the availability of generic injectables.

Emerging Opportunities:

• Growth in Emerging Markets: Increasing access to healthcare and rising infection rates in developing economies can create new demand for essential antibiotics like tobramycin.
• Targeted Use Against Specific MDROs: In situations where newer agents are ineffective or unavailable, tobramycin may retain or regain importance for specific multidrug-resistant organisms if susceptibility testing supports its use.
• Development of Novel Formulations (Limited Scope): While major patentable innovations are unlikely, incremental improvements in drug delivery or formulation stability could offer minor competitive advantages, although significant R&D investment is improbable for such a mature generic.
• Partnerships and Strategic Alliances: Manufacturers could form alliances for distribution or co-promotion, especially to navigate complex hospital procurement processes.

What is the impact of regulatory changes and evolving guidelines on the market?

Regulatory changes and evolving clinical guidelines have a significant impact:

• FDA/EMA Approval Pathways: Ensuring compliance with evolving GMP standards, sterile manufacturing requirements, and bioequivalence testing standards is critical for market entry and continued supply.
• Antibiotic Stewardship Guidelines: Recommendations from bodies like the Infectious Diseases Society of America (IDSA) or national health organizations (e.g., NICE in the UK) influence prescribing practices. These guidelines often emphasize the judicious use of broad-spectrum antibiotics and prioritize agents with better safety profiles or specific activity against identified pathogens. This can lead to a more targeted, and potentially reduced, use of tobramycin.
• Drug Shortage Management: Regulatory agencies focus on preventing and managing drug shortages. Manufacturers who can consistently supply the market are favored.
• Pharmacovigilance and Post-Market Surveillance: Increased scrutiny of drug safety profiles, including the nephrotoxicity and ototoxicity of aminoglycosides, can influence prescribing preferences and lead to more stringent monitoring requirements.
• Environmental Regulations: Evolving regulations concerning manufacturing waste and emissions can impact production costs and facility operations.

Key Takeaways

• The tobramycin sulfate in sodium chloride 0.9% injection market is a mature, high-volume, generic sector characterized by intense price competition and supply chain reliability as key differentiators.
• Original patents have expired, leading to a fragmented supplier landscape dominated by established generic manufacturers.
• Market growth is projected to be modest, driven by persistent bacterial infection rates but constrained by antibiotic stewardship initiatives and the availability of newer therapeutic alternatives.
• Key revenue drivers include hospital formularies, GPO contracts, and the drug's cost-effectiveness in treating a broad spectrum of susceptible bacterial infections.
• Emerging threats include increasingly stringent antibiotic stewardship, potential development of novel resistance patterns, and consolidation of purchasing power.
• Opportunities exist in emerging markets and for targeted use against specific multidrug-resistant organisms when supported by susceptibility data.
• Regulatory compliance, particularly with sterile manufacturing standards, and adherence to evolving clinical guidelines are critical for sustained market participation.

Frequently Asked Questions

1. What is the typical shelf life and storage condition for tobramycin sulfate in sodium chloride 0.9% injection? The typical shelf life for most generic tobramycin sulfate in sodium chloride 0.9% injection products is 24 to 36 months from the date of manufacture, provided they are stored under recommended conditions. Storage generally requires room temperature (e.g., 20°C to 25°C or 68°F to 77°F), protected from light and freezing. Specific storage instructions are detailed on individual product packaging and labeling.

2. How does tobramycin sulfate in sodium chloride 0.9% injection compare in efficacy to other aminoglycosides for specific infections? While all aminoglycosides share a similar spectrum of activity, specific efficacy can vary by organism and infection site. Tobramycin is often a preferred choice for infections caused by Pseudomonas aeruginosa due to its good activity. Gentamicin has a slightly narrower spectrum but is also widely used. Amikacin typically exhibits broader activity, including against some strains resistant to gentamicin and tobramycin. The choice between aminoglycosides depends heavily on local susceptibility patterns, specific pathogen identification, and the patient's clinical status.

3. What are the primary methods used to monitor for toxicity (nephrotoxicity and ototoxicity) when administering tobramycin sulfate? Monitoring for toxicity involves a combination of clinical assessment and laboratory tests. Nephrotoxicity is monitored by tracking serum creatinine levels and calculating creatinine clearance. Ototoxicity is assessed through audiometric testing and by monitoring for subjective symptoms like tinnitus or hearing loss. Therapeutic drug monitoring (TDM), specifically measuring peak and trough serum concentrations of tobramycin, is crucial to ensure efficacy while minimizing the risk of toxicity.

4. Can tobramycin sulfate in sodium chloride 0.9% injection be mixed with other intravenous medications in the same infusion bag? Incompatibility issues can arise when mixing tobramycin sulfate with other drugs. While it is generally compatible with common intravenous solutions like 0.9% sodium chloride and 5% dextrose, it can be chemically or physically incompatible with certain beta-lactam antibiotics (e.g., penicillins and cephalosporins), certain heparin preparations, and intravenous lipid emulsions. Therefore, it is generally recommended to administer tobramycin sulfate separately, through a dedicated IV line or by flushing the line thoroughly between administrations, unless specific compatibility studies confirm safety for co-administration. Prescribers and pharmacists must consult detailed compatibility charts.

5. What is the role of tobramycin sulfate in sodium chloride 0.9% injection in treating ventilator-associated pneumonia (VAP)? Tobramycin sulfate may be included in treatment regimens for ventilator-associated pneumonia (VAP), particularly when Pseudomonas aeruginosa or other Gram-negative pathogens susceptible to tobramycin are suspected or confirmed. VAP guidelines often recommend combination therapy, especially for high-risk patients or when multidrug-resistant organisms are prevalent. Tobramycin, as part of an appropriate antibiotic combination, can help broaden coverage against Gram-negative bacteria. However, current stewardship practices emphasize tailoring therapy based on Gram stain, culture results, and local antibiograms to avoid unnecessary broad-spectrum use and minimize resistance development.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Drug Development & Review. Retrieved from [FDA website] (General information on regulatory processes for generics).

[2] European Medicines Agency. (n.d.). Medicines. Retrieved from [EMA website] (General information on regulatory processes for generics in the EU).

[3] Infectious Diseases Society of America. (Various publications). Clinical Practice Guidelines. Retrieved from [IDSA website] (Information on antibiotic treatment guidelines).

[4] Individual pharmaceutical company product insert information (e.g., Fresenius Kabi, Hikma Pharmaceuticals, Baxter, Sandoz, Teva, Viatris). (Accessed via manufacturer websites or drug databases).

[5] Various market research reports on the global antibiotics market. (Reports by firms such as Grand View Research, MarketsandMarkets, Allied Market Research).